Answers are grounded in this paper and cite their sources.
Antimicrobial peptide LL37, a cationic small peptide composed of 37 amino acids, serves as a potential biomarker for autoimmune diseases. However, its quantitative detection remains challenging due to its low molecular weight and poor immunogenicity. Therefore available methods of LL37 detection are often complex, time-consuming, and expensive. In this study, a magnetic microsphere fluorescence assay based on a nucleic acid aptamer was developed for LL37 quantification. The aptamer (Apt-01) was labeled with Cy3 and biotin at the end of 3′ and 5′, respectively, and a BHQ2-labeled complementary DNA served as a quencher. Upon target binding, a dose-dependent fluorescence recovery consistent with cDNA displacement by LL37 was observed. Under optimized aptamer and cDNA concentrations, as well as incubation time, the assay exhibited a favorable linear range of 0.5–20 ng/mL (R2 = 0.9941) with a limit of detection of 0.089 ng/mL. Spike recovery rates ranged from 85% to 116% with relative standard deviations below 10%. Moreover, the detection results of LL37 showed good concordance with those of a commercial ELISA kit, with deviations of RSD in ±3.0%. In conclusion, the aptamer-based microsphere fluorescence assay offers a practical alternative to antibody dependent approaches for LL37 detection. This platform also holds great potential for broad application in autoimmune disease diagnostics.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: